Fibroblast growth factor 1 protein fragments and methods of use
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
1. A method of treating a mammal having diabetes, comprising:
administering an FGF1 peptide comprising amino acids 1-155 of SEQ ID NO: 1 with a K127D, K128Q and K133V substitution (FGF1 ΔHBS ) in an amount effective to lower blood glucose levels in the mammal, thereby treating the mammal.
2. The method of claim 1 , wherein the mammal has one or more of type 1 diabetes, type 2 diabetes, gestational diabetes, and drug-induced diabetes.
3. The method of claim 1 , wherein the FGF1 peptide is administered at a dose of 0.1 to 10 mg/kg once or twice a day.
4. The method of claim 1 , wherein the FGF1 peptide is administered at a dose of 0.5 mg/kg.
5. The method of claim 1 , wherein administering comprises oral, parenteral, subcutaneous, intravenous, intramuscular, or intraperitoneal administration.
6. The method of claim 1 , wherein the FGF1 peptide is administered with a pharmaceutically-acceptable carrier.
7. The method of claim 1 , wherein the FGF1 peptide is co-administered with one or more agents selected from the group consisting of an anti-inflammatory agent, an antifibrotic agent, an antihypertensive agent, an antidiabetic agent, a triglyceride-lowering agent, and a cholesterol-lowering agent.
8. The method of claim 1 , wherein the mammal is a human.
9. The method of claim 1 , wherein the FGF1 peptide consists of the amino acid sequence shown in:
amino acids 1-155 of SEQ ID NO: 1 with a K127D, K128Q and K133V substitution (FGF1 ΔHBS ).
10. A method of treating a mammal having diabetes, comprising:
administering an FGF1 peptide fragment comprising amino acids 25-155 of SEQ ID NO: 1 with a K127D, K128Q and K133V substitution (FGF1 ΔNT ΔHBS ) in an amount effective to lower blood glucose levels in the mammal, thereby treating the mammal.
11. The method of claim 10 , wherein the mammal has one or more of type 1 diabetes, type 2 diabetes, gestational diabetes, and drug-induced diabetes.
12. The method of claim 10 , wherein the FGF1 peptide fragment is administered at a dose of 0.1 to 10 mg/kg once or twice a day.
13. The method of claim 10 , wherein the FGF1 peptide fragment is administered at a dose of 0.5 mg/kg.
14. The method of claim 10 , wherein administering comprises oral, parenteral, subcutaneous, intravenous, intramuscular, or intraperitoneal administration.
15. The method of claim 10 , wherein the FGF1 peptide fragment is administered with a pharmaceutically-acceptable carrier.
16. The method of claim 10 , wherein the FGF1 peptide fragment is co-administered with one or more agents selected from the group consisting of an anti-inflammatory agent, an antifibrotic agent, an antihypertensive agent, an antidiabetic agent, a triglyceride-lowering agent, and a cholesterol-lowering agent.
17. The method of claim 10 , wherein the mammal is a human.
18. The method of claim 10 , wherein the FGF1 peptide fragment consists of the amino acid sequence shown in amino acids 25-155 of SEQ ID NO: 1 with a K127D, K128Q and K133V substitution (FGF1 ΔNT ΔHBS ) .
19. A method of treating a mammal having diabetes, comprising:
administering an FGF1 peptide fragment consisting of amino acids 25-155 of SEQ ID NO: 1 (FGF1 ΔNT ) in an amount effective to lower blood glucose levels in the mammal, thereby treating the mammal.
20. The method of claim 19 , wherein the mammal has one or more of type 1 diabetes, type 2 diabetes, gestational diabetes, drug-induced diabetes, and high blood glucose.
21. The method of claim 19 , wherein the FGF1 peptide fragment is administered at a dose of 0.1 to 10 mg/kg once or twice a day.
22. The method of claim 19 , wherein the FGF1 peptide fragment is administered at a dose of 0.5 mg/kg.
23. The method of claim 19 , wherein administering comprises oral, parenteral, subcutaneous, intravenous, intramuscular, or intraperitoneal administration.
24. The method of claim 19 , wherein the FGF1 peptide fragment is administered with a pharmaceutically-acceptable carrier.
25. The method of claim 19 , wherein the FGF1 peptide fragment is co-administered with one or more agents selected from the group consisting of an anti-inflammatory agent, an antifibrotic agent, an antihypertensive agent, an antidiabetic agent, a triglyceride-lowering agent, and a cholesterol-lowering agent.
26. The method of claim 19 , wherein the mammal is a human.